Affiliate Disclosure: MiraviGLP earns a commission when you purchase through links on this site. This does not affect our rankings or editorial independence. Learn more
Buy Retatrutide
Peptide From
The Best Vendor
Independent rankings of high-purity GLP peptide suppliers. KOI Peptides rated #1 US vendor — ISO/IEC 17025 accredited testing, lot-specific COAs, and same-day dispatch.
99.2%
HPLC Purity
#1
KOI Peptides Rated
ISO 17025
Accredited Lab
Retatrutide
Triple GLP-1 / GIP / GCG Agonist
≥99.2% HPLC
Freedom Diagnostics · ISO 17025
Research peptides for in-vitro laboratory use only. Not for human consumption. Affiliate disclosure: commissions earned on purchases.
Research Peptides Available Now
We recommend KOI Peptides — the top-ranked US supplier with ISO/IEC 17025 accredited batch testing and lot-specific COAs on every order.
Retatrutide
Retatrutide · Triple GLP-1/GIP/GCG Agonist
Sizes: 10 mg · 30 mg
Tirzepatide
Dual GIP/GLP-1 Agonist
Sizes: 10 mg · 30 mg
Tesamorelin
GH-Releasing Factor Analog
Sizes: 2 mg · 5 mg
AOD-9604
GH Fragment 177-191
Sizes: 5 mg · 10 mg
MOTS-c
Mitochondrial Derived Peptide
Sizes: 5 mg · 10 mg
Cagrilintide
Long-Acting Amylin Analog
Sizes: 2 mg · 5 mg
5-Amino-1MQ
NNMT Inhibitor · NAD+ Precursor
Sizes: 50 mg · 100 mg
All products are for qualified in-vitro laboratory research use only. Not for human or animal consumption. We may earn an affiliate commission on purchases made through our links — this does not affect vendor rankings.
How we evaluate compound safety
Every vendor we rank is evaluated against a six-point safety and quality framework. Here is what each checkpoint covers and why it matters for accurate in-vitro research.
HPLC Purity ≥ 99%
At sub-99% purity, uncharacterized impurities interact non-specifically with cell-surface receptors and downstream signaling enzymes, introducing noise that compromises dose-response reproducibility. Our minimum ranked standard is 98% HPLC; the preferred gold-standard is ≥99.2% with LC-MS identity confirmation on the same batch.
Endotoxin Testing (LAL / rFC)
Bacterial endotoxins (LPS) trigger innate immune signaling in mammalian cell cultures at sub-nanogram concentrations, causing false-positive cytotoxicity and confounding metabolic assays. Every vendor we rank must supply a USP LAL or recombinant Factor C (rFC) endotoxin result alongside HPLC purity — this is especially critical for GLP receptor cell-line work.
Cold-Chain Storage Standards
Lyophilized GLP-class peptides are stable at -20°C for 12-24 months, or at -80°C for maximum long-term stability. Once reconstituted, store at 4°C and use within 7 days; for longer storage, aliquot and freeze at -20°C. Avoid repeated freeze-thaw cycles — each cycle degrades peptide integrity and lowers effective purity in your working solution.
Reconstitution Protocol
Reconstitute lyophilized GLP peptides in sterile bacteriostatic water or sterile PBS, depending on your protocol. Add solvent slowly to the lyophilized cake — do not vortex. Use gentle swirling or rotation only. For retatrutide (triple GLP-1/GIP/glucagon agonist) and tirzepatide (dual GIP/GLP-1 agonist), allow 10-15 minutes for complete dissolution before drawing aliquots to avoid aggregation artefacts.
5-Point Documentation Checklist
Before using any batch: (1) confirm the lot number on the vial matches the COA exactly; (2) verify the HPLC assay date is within 24 months; (3) check purity ≥98% (≥99% preferred); (4) confirm LC-MS identity peak matches the expected molecular weight; (5) confirm endotoxin result is present and within spec. Vendors missing any of these five data points are not ranked in our top tier.
ISO/IEC 17025 Independent Lab Accreditation
In-house COAs and batch-average documentation do not meet our standard. Top-ranked vendors must use an ISO/IEC 17025 accredited third-party laboratory for per-batch HPLC and LC-MS analysis. Accreditation means the lab's measurement uncertainty, equipment calibration, and personnel competency have been independently audited — making the COA result legally and scientifically defensible.
All compounds listed are for qualified in-vitro laboratory research use only by trained scientific professionals. Not for human or animal consumption.
Why researchers trust MiraviGLP
Why these compounds matter in research
GLP-class peptides are among the most scientifically productive research compounds of the past decade. Here is what makes each one valuable in an in-vitro laboratory setting.
Semaglutide
The most studied incretin peptide
GLP-1 receptor agonists have been the subject of thousands of peer-reviewed studies over the past two decades. Researchers use Semaglutide analogs to investigate GLP-1 receptor signaling, pancreatic beta-cell function, appetite regulation pathways, and metabolic homeostasis in vitro. Its well-characterized mechanism makes it a gold-standard research tool for incretin biology.
9,400+
PubMed citations
>94%
Receptor affinity
~168h
Half-life (research)
Tirzepatide
Dual-receptor agonism unlocks new pathways
Tirzepatide simultaneously activates GLP-1 and GIP receptors, making it uniquely valuable for researchers studying the intersection of two distinct incretin axes. In-vitro studies use it to probe differential downstream signaling, receptor cross-talk, and synergistic effects on cAMP production and insulin secretion modeling that single-agonist compounds cannot replicate.
2 (GLP-1 + GIP)
Receptors targeted
~22% wt. reduction
SURMOUNT data
Dual pathway
cAMP potency
Retatrutide
Triple agonism: the frontier of GLP research
Retatrutide (LY3437943) adds glucagon receptor agonism to the GLP-1 + GIP dual axis, creating the most complex incretin-class research compound available. The glucagon component increases hepatic glucose output and energy expenditure modeling, making it a critical tool for researchers studying thermogenic pathways, fatty acid oxidation, and the additive effects of triple receptor co-activation in metabolic cell models.
3 (GLP-1, GIP, GCG)
Receptors targeted
~24.2%
Phase 3 wt. data
Triple G
Community name
All compounds are sold strictly for in-vitro laboratory research use by qualified researchers. Not for human or animal consumption.
How the Miravi Score works
Every company on MiraviGLP is scored out of 100 across seven independently weighted criteria before appearing in our rankings. No vendor pays for placement. The same framework applies to all.
Independent third-party testing
We require an ISO/IEC 17025 accredited external lab running at minimum HPLC purity analysis and LC-MS identity confirmation per batch. In-house numbers alone are never accepted.
Lot-specific COA documentation
Every COA must match the exact lot number on the vial, carry a date, and be signed. A generic PDF that never changes across batches is treated as a red flag.
Endotoxin and sterility data
For compounds intended for reconstitution in solution, USP endotoxin testing against a pharmacopeial standard confirms the material was handled under clean synthesis conditions.
Sourcing transparency
Where is it synthesized? Who owns the company? Is there a verifiable US address? Domestic synthesis with a named legal entity and registered business address beats anonymous overseas drop-shipping.
Honest labeling and regulatory record
Research suppliers must label products as research-use-only and must not provide human dosing guidance. Any vendor marketing therapeutic use on research vials is immediately excluded.
Community verification and forum testing
We aggregate independent purity data from researcher forums and communities where anonymous third-party buyers have submitted vials for independent mass spec analysis. Crowd-sourced data supplements our editorial review.
Fulfillment reliability and supply chain
We evaluate dispatch speed, cold-chain packaging practices, and reorder consistency based on community-reported shipping experiences and publicly available vendor documentation. A vendor who delivers excellent documentation but cannot maintain stock or ship promptly is ranked lower.
Who builds the Miravi Score
Our rankings are maintained by a team with backgrounds in biochemistry, laboratory QA, and independent compound testing. Vendor scores are updated continuously — not just at launch.
Dr. Elena Reyes
Lead Research Analyst
Biochemist with 11 years in academic peptide synthesis research. Leads vendor COA auditing and develops Miravi Score criteria across new compound categories. Previously a research scientist at a US university peptide core facility.
James Kwan
COA Documentation Specialist
Former laboratory QA coordinator with a background in HPLC documentation review and batch-level traceability. Manages COA documentation review standards and maintains verification criteria across all ranked vendors.
Marcus Webb
Research Scientist
In-vitro research scientist specializing in GLP receptor agonist pharmacology. Reviews vendor purity methodology for accuracy and alignment with current in-vitro research protocols. Advises on incretin compound classification and assay interpretation.
Sarah Okafor
Community & Data Analyst
Aggregates and validates independent purity reports from researcher communities, peptide forums, and academic lab networks. Monitors vendor reputation data continuously and flags community-sourced quality signals for editorial review.
Continuous monitoring, not just annual reviews
The team actively monitors vendor COA updates, community-sourced purity data, regulatory events, and fulfillment reports on an ongoing basis. Rankings are updated whenever new material information becomes available — not on a fixed calendar. Vendors can move up or down based on documentation changes, FDA actions, community testing results, or ownership changes.
The research community is talking
See what qualified researchers and the broader peptide community are sharing about GLP-class compounds and company quality.
From the research community
Illustrative feedback reflecting common researcher use cases. Names withheld.
"The COA breakdown cut my vendor vetting time significantly. Their documentation standards section alone flagged two vendors whose purity claims didn't hold up — saved me from a bad sourcing decision before it happened."
R.M.
Independent research lab
"The per-mg cost comparison paired with purity tier analysis is what I needed. Most review sites don't go deep enough on documentation standards. This one actually does the work."
Lab coordinator
University research program
"Found a Tirzepatide source with actual batch-level third-party COAs through their rankings — something I couldn't locate after three weeks on community forums. The documentation matched exactly what my protocol required."
Peptide researcher
Private laboratory, Pacific Northwest
Buy Retatrutide Peptide: The Researcher's Guide to US Peptide Suppliers
What Is Miravi GLP1?
Miravi GLP1 is the research-focused editorial platform dedicated to independently ranking and reviewing the best GLP-1 peptide vendors for in-vitro laboratory researchers. Unlike paid directories or affiliate-first review aggregators, Miravi GLP1 rankings are built entirely on verifiable metrics: HPLC purity documentation, Certificate of Analysis transparency, shipping reliability, catalog depth, and aggregated feedback from active research communities.
The platform was created by peptide researchers who found the sourcing landscape for GLP-1 compounds frustratingly opaque. As semaglutide became one of the most studied GLP-1 receptor agonist research peptides in the world, the number of vendors claiming pharmaceutical-grade purity exploded while documentation standards remained wildly inconsistent. Miravi GLP1 applies rigorous editorial criteria to vendor evaluation so that researchers can make informed sourcing decisions without spending hours cross-referencing community forums.
All compounds referenced in Miravi GLP1 rankings are sold strictly for qualified in-vitro laboratory research by trained scientific professionals. Nothing on this site constitutes medical advice, and no compound listed is recommended for human or animal consumption.
GLP-1 Semaglutide: The Foundation of Incretin Research
GLP-1 (Glucagon-Like Peptide-1) receptor agonists have been the subject of more than 9,400 peer-reviewed publications over the past two decades. Semaglutide, the synthetic GLP-1 analog modeled on the endogenous GLP-1(7-37) peptide, carries approximately 94% structural homology with native human GLP-1. Its albumin-binding modifications extend its half-life significantly, making it a particularly useful tool in in-vitro research settings where sustained receptor activation over extended incubation periods is experimentally desirable.
Researchers use GLP-1 semaglutide analogs across a range of in-vitro contexts: pancreatic beta-cell models to study insulin secretion and beta-cell survival signaling, hypothalamic neuron cultures to examine appetite-regulation pathway activation, hepatocyte models to probe GLP-1 receptor-mediated glucose production suppression, and adipocyte studies investigating the relationship between incretin signaling and lipid metabolism. Semaglutide's well-characterized receptor affinity profile and published pharmacokinetic data make it the preferred reference agonist for incretin biology research.
Research-grade semaglutide is supplied as a lyophilized powder intended for reconstitution in sterile research buffer by qualified laboratory personnel. Published in-vitro protocols typically use concentrations spanning 0.25 mg to 2.5 mg per experimental unit, though specific requirements vary by protocol and cell model. Purity is a critical variable: a semaglutide sample at 92% purity introduces approximately 8% unknown impurities that may interact non-specifically with receptors or downstream signaling enzymes, confounding dose-response curves and compromising data reproducibility across experimental runs.
The Miravi GLP1 ranking standard requires a minimum of 98% HPLC-verified purity from a per-batch, independently verified Certificate of Analysis before a vendor is eligible for top-tier ranking consideration. Vendors at 99%+ purity with public ISO/IEC 17025 accredited independent lab documentation are assigned gold-standard documentation status.
How Miravi GLP1 Rankings Work
The Miravi GLP1 ranking methodology evaluates vendors across seven independently weighted criteria. Rankings are updated quarterly or whenever significant new information becomes available, including new COA practices, community feedback changes, catalog updates, or ownership changes that may affect quality.
The first and most heavily weighted criterion is purity documentation quality. Miravi GLP1 recognizes per-batch, third-party HPLC Certificates of Analysis as the minimum acceptable documentation standard. The current gold standard is a COA from an ISO/IEC 17025 accredited independent laboratory: the lab runs HPLC purity and LC-MS identity analysis on the specific batch being sold and issues a signed, lot-specific result. Vendors providing only in-house COAs, batch-average documentation, or request-only paperwork receive lower documentation scores.
The second criterion is catalog depth, evaluating whether the vendor stocks the full range of GLP-1, tirzepatide (dual agonist), and retatrutide analogs in clinically relevant dosages alongside related incretin compounds such as Cagrilintide and Retatrutide. The third criterion is shipping reliability, measured against community-reported dispatch and delivery times for US domestic and international customers. The fourth is price per milligram relative to documented purity tier. The fifth is community reputation drawn from active researcher forums. The sixth is business transparency, including verifiable physical address, clear return and quality guarantee policies, and responsive customer support.
No vendor pays for placement in Miravi GLP1 rankings. Affiliate commissions are earned when researchers purchase through tracked links, but these commissions do not influence ranking positions. The methodology is applied identically to all vendors regardless of commercial relationships.
Sourcing GLP-1 Peptides for Research: What to Look For
Selecting a GLP-1 vendor for laboratory research requires evaluating documentation quality before pricing. The most common mistake new researchers make is choosing vendors based on per-milligram cost without reviewing COA standards first. A semaglutide batch at 89% purity priced at $30/mg is not equivalent to a 99.2% HPLC-verified batch at $50/mg, even though both may be marketed as research-grade semaglutide. The 10% purity differential represents uncharacterized impurities with unknown receptor interactions that will introduce noise into any downstream assay.
The first check for any GLP-1 vendor is COA availability and format. Acceptable documentation includes a publicly accessible, per-batch HPLC Certificate of Analysis from a named and verifiable third-party laboratory; a batch number that corresponds to the specific order; a purity result of at least 98% (with 99%+ preferred for precision quantitative research); and an assay date within the last 18 to 24 months. Vendors who cannot produce documentation meeting these criteria should not be considered for research applications where data integrity is a priority.
The second check is geographic shipping origin. Domestic US-based vendors generally provide same-day to five-day delivery, cleaner supply-chain documentation, and no import compliance burden. International vendors, primarily European, may offer competitive pricing and greater availability for specialty nootropic peptides, but transit times run 7 to 21 days and import regulations vary by state and compound category.
The third check is catalog consistency across reorder cycles. Researchers frequently need to source the same compound at the same purity level across multiple experimental runs spanning months or years. A vendor who delivers excellent initial documentation but cannot maintain batch-to-batch purity consistency or catalog availability creates compounding logistical problems for longitudinal research programs. Miravi GLP1 tracks reorder reliability as part of its ongoing community feedback evaluation.
Semaglutide vs Tirzepatide vs Retatrutide: Choosing the Right Compound for Your Protocol
Miravi GLP1 covers the full family of GLP receptor agonist compounds used in current in-vitro research. Understanding the mechanistic differences between single-agonist (semaglutide), dual-agonist (tirzepatide), and triple-agonist (retatrutide) compounds is essential for designing protocols that correctly isolate the intended receptor pathway without introducing confounding receptor cross-activation.
GLP-1 (semaglutide) is a selective GLP-1 receptor agonist targeting the GLP-1R with high specificity and minimal off-target receptor activity at research-relevant concentrations. This selectivity makes semaglutide the reference compound for all studies aiming to isolate GLP-1 receptor signaling, including pancreatic beta-cell function, hypothalamic appetite regulation, and hepatic glucose metabolism through the GLP-1 pathway alone. For research requiring clean GLP-1 receptor isolation, semaglutide is the established standard. See our full GLP-1 vendor rankings for current sourcing options.
Tirzepatide is a dual GIP/GLP-1 receptor agonist activating both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide receptor simultaneously. This dual-receptor pharmacology produces distinct downstream signaling compared to pure GLP-1 receptor agonism, including synergistic insulin secretion enhancement and differential effects on adipose tissue metabolism. Tirzepatide is appropriate for research specifically examining the interaction between GLP-1 and GIP receptor pathways and cannot serve as a direct substitute for semaglutide in GLP-1 receptor-only study designs. See our Tirzepatide vendor rankings.
Retatrutide (LY3437943) is a triple agonist targeting GLP-1R, GIPR, and the glucagon receptor simultaneously. Triple agonism introduces hepatic glucagon receptor activation effects absent in both semaglutide and tirzepatide protocols, including differential modulation of hepatic glucose output and adipose fatty acid oxidation. Retatrutide is suited for research examining multi-receptor incretin pharmacology, not as a replacement compound in existing GLP-1 or tirzepatide (dual agonist) study designs. See our Retatrutide vendor rankings.
Where to Buy Retatrutide Peptide from a US Supplier in 2026
KOI Peptides is the top-ranked US supplier for retatrutide (LY3437943) in the 2026 MiraviGLP evaluation cycle, holding a 95/100 Miravi Score across GLP-1, tirzepatide, and retatrutide categories. For researchers looking to buy retatrutide peptide from a US supplier, KOI is the benchmark: every batch is synthesized and lyophilized in the United States and independently tested by an ISO/IEC 17025 accredited external laboratory before dispatch. The ranking reflects performance across all seven editorial criteria, with particular strength in documentation quality, sourcing transparency, and community-verified purity data.
On testing documentation, each KOI lot is sent to an independent ISO/IEC 17025 accredited laboratory running three assays: HPLC for purity percentage, LC-MS (liquid chromatography-mass spectrometry) for molecular identity confirmation, and USP endotoxin testing for sterility. The lot-specific COA covering all three results is published in a searchable public COA library, so researchers can verify their specific batch before it arrives rather than trusting a stock document.
On sourcing transparency, KOI synthesizes and lyophilizes its peptides in the United States and operates as a US-registered entity out of Sheridan, Wyoming. The company catalogs 100+ compounds and blends with institutional and wholesale pricing for universities and labs, which reduces the documentation overhead of managing multiple supplier relationships.
On shipping reliability, KOI Peptides offers same-day dispatch from their US domestic facility for orders placed before their daily cutoff, with 2 to 5 business day delivery consistently reported across the continental United States. Visit KOI Peptides or read our full KOI Peptides review.